Panaquell

PANOQUELL-CA1 (fuzapladib sodium) is an injectable veterinary medication conditionally approved by the FDA to manage clinical signs associated with acute pancreatitis in dogs.

Unlike traditional supportive treatments, PANOQUELL-CA1 targets a specific part of the inflammatory response. However, it is not a cure for pancreatitis and does not replace appropriate nutrition, hydration, pain management, or veterinary monitoring.

From a holistic perspective, it’s important to look beyond the immediate episode. Factors such as dietary fat, obesity, underlying metabolic conditions, and certain medications may contribute to pancreatitis in some dogs. Identifying individual risk factors can be an important part of reducing future episodes.

How Does PANOQUELL-CA1 Work?

PANOQUELL-CA1 inhibits the activation of leukocyte function-associated antigen-1 (LFA-1), a protein involved in the movement of inflammatory white blood cells into injured tissues.

By limiting this movement, the medication is intended to reduce aspects of the inflammatory response associated with acute pancreatitis.

What Holistic Pet Parents Should Know

• Designed for Acute Pancreatitis: It is intended to manage clinical signs associated with acute-onset pancreatitis in dogs, not prevent future episodes.

• FDA Conditional Approval: The FDA determined that the medication met safety requirements and demonstrated a reasonable expectation of effectiveness, but full effectiveness had not been established at the time of conditional approval.

• Veterinary Administration Required: It is given intravenously by a veterinarian, typically once daily for three consecutive days.

• Not a Replacement for Supportive Care: Dogs may still require fluids, pain relief, anti-nausea medication, and nutritional support.

• Individual Risk Assessment Matters: Dogs with certain pre-existing medical conditions may require additional caution.

Potential Side Effects and Safety Concerns

Reported adverse reactions include decreased appetite, digestive tract problems, respiratory disorders, liver-related abnormalities, and jaundice.

Post-approval reports from another market have also included facial or tongue swelling, collapse, and seizures. These reports do not necessarily establish that the medication caused every event.

Safety has not been adequately evaluated in dogs with cardiac disease, hepatic failure, kidney impairment, puppies younger than six months, or dogs that are pregnant, nursing, or intended for breeding.

Pet parents should discuss these risks and their dog’s medical history with their veterinarian before treatment.

Holistic Support Alongside Veterinary Treatment

Nutrition First

Once your veterinarian determines that feeding is appropriate, a highly digestible, nutritionally balanced diet with an appropriate fat content can support recovery. Fresh, gently cooked food may be an option when formulated for the dog’s nutritional needs.

Digestive and Microbiome Support

Some dogs may benefit from carefully selected probiotics or other digestive support, particularly when they have additional gastrointestinal problems. However, these products have not been established as treatments for acute pancreatic inflammation.

Supplements and Antioxidants

Omega-3 fatty acids, antioxidants, NAC, glutathione-support products, and digestive enzymes are sometimes discussed in integrative care. 

Environmental and Lifestyle Considerations

Maintaining a healthy weight, avoiding fatty table scraps, managing underlying medical conditions, and reviewing medications with your veterinarian may help reduce certain pancreatitis risk factors.

The Bottom Line

PANOQUELL-CA1 may be one component of veterinary treatment for acute pancreatitis in dogs. Its potential benefits must be weighed against its risks and the limitations of available evidence.

An integrative approach combines appropriate medical care during an acute episode with individualized nutrition and long-term management of contributing factors.